Abstract
AHT was an international, non-blinded phase III RCT designed to assess whether administering adjuvant hormone therapy (AHT) after ovarian cancer affects overall survival (OS). Between 1990-1995, 150 patients were randomised to receive AHT (n=75) or no AHT (Control, n=75). Death data for UK patients (83% of total) provided by the Health and Social Care Information Centre (HSCIC) has allowed long-term follow-up and therefore detailed investigation into the pattern of events over time. At time of data snapshot, median follow-up was 19yrs.
Highlights
AHT was an international, non-blinded phase III RCT designed to assess whether administering adjuvant hormone therapy (AHT) after ovarian cancer affects overall survival (OS)
Restricted Mean Survival (RSM) is an effective method for analysing survival data in the presence of non-presence of nonproportional hazards (PH), choice of t* may affect robustness of results
Absolute difference between survival estimates in each group was plotted against time and compared to inclusion of a time-dependent covariate in a Cox-PH model
Summary
AHT was an international, non-blinded phase III RCT designed to assess whether administering adjuvant hormone therapy (AHT) after ovarian cancer affects overall survival (OS). Between 1990-1995, 150 patients were randomised to receive AHT (n=75) or no AHT (Control, n=75). Death data for UK patients (83% of total) provided by the Health and Social Care Information Centre (HSCIC) has allowed long-term follow-up and detailed investigation into the pattern of events over time. At time of data snapshot, median follow-up was 19yrs
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
